# Soong-Daystrom Industries, Inc.
## Quarterly Financial Reports - FY 2124

**NASDAQ: SDAI**

---

# Q1 2124 Quarterly Report
## For the Quarter Ended March 31, 2124

### Executive Summary

Soong-Daystrom Industries delivered a strong start to fiscal 2124, with revenue of $11.2 billion representing 14.3% year-over-year growth. All four business segments contributed to growth, with Neural Interface Modules continuing to lead at 42% growth. We are reaffirming our full-year guidance and remain confident in our strategic direction.

### Financial Highlights

| Metric | Q1 2124 | Q1 2123 | YoY Change |
|--------|---------|---------|------------|
| Revenue | $11.2B | $9.8B | +14.3% |
| Gross Profit | $5.7B | $4.9B | +16.3% |
| Gross Margin | 50.9% | 50.0% | +90 bps |
| Operating Income | $1.6B | $1.3B | +23.1% |
| Operating Margin | 14.3% | 13.3% | +100 bps |
| Net Income | $1.2B | $1.0B | +20.0% |
| Diluted EPS | $1.31 | $1.09 | +20.2% |
| Free Cash Flow | $0.9B | $0.7B | +28.6% |

### Non-GAAP Reconciliation

| Metric | Q1 2124 | Q1 2123 | Change |
|--------|---------|---------|--------|
| GAAP Net Income | $1.2B | $1.0B | +20.0% |
| Stock-based compensation | $0.21B | $0.19B | |
| Amortization of intangibles | $0.08B | $0.08B | |
| Restructuring charges | $0.02B | $0.01B | |
| **Adjusted Net Income** | **$1.51B** | **$1.28B** | **+18.0%** |
| | | | |
| GAAP Diluted EPS | $1.31 | $1.09 | +20.2% |
| Non-GAAP adjustments | $0.23 | $0.21 | |
| **Adjusted Diluted EPS** | **$1.54** | **$1.30** | **+18.5%** |

### Revenue by Segment

| Segment | Q1 2124 | Q1 2123 | YoY Change | % of Total |
|---------|---------|---------|------------|------------|
| PCS | $4.6B | $4.2B | +9.5% | 41.1% |
| IAP | $3.7B | $3.1B | +19.4% | 33.0% |
| NIM | $1.6B | $1.1B | +45.5% | 14.3% |
| SCE | $0.8B | $0.9B | -11.1% | 7.1% |
| Other | $0.5B | $0.5B | +0.0% | 4.5% |
| **Total** | **$11.2B** | **$9.8B** | **+14.3%** | **100%** |

### Revenue by Geography

| Region | Q1 2124 | Q1 2123 | YoY Change | % of Total |
|--------|---------|---------|------------|------------|
| North America | $5.8B | $5.1B | +13.7% | 51.8% |
| Europe | $1.9B | $1.7B | +11.8% | 17.0% |
| Asia-Pacific | $2.8B | $2.4B | +16.7% | 25.0% |
| Rest of World | $0.7B | $0.6B | +16.7% | 6.2% |
| **Total** | **$11.2B** | **$9.8B** | **+14.3%** | **100%** |

### Segment Performance Details

#### Positronic Companion Series (PCS)

**Q1 2124 Revenue**: $4.6 billion (+9.5% YoY)

| Metric | Q1 2124 | Q1 2123 | Change |
|--------|---------|---------|--------|
| Units Shipped | 168,000 | 158,000 | +6.3% |
| Average Selling Price | $23,810 | $23,418 | +1.7% |
| Service Revenue | $1.1B | $1.0B | +10.0% |
| Operating Margin | 17.8% | 16.9% | +90 bps |

**Key Developments**:
- PCS-250 "Companion Lite" launched in March 2124, exceeding initial sales targets
- PCS-500 Elite continued strong performance in premium segment
- Service network expanded to 892 locations globally
- Customer satisfaction maintained at 94%

**Commentary**: The successful launch of PCS-250 opens a new market segment for first-time companion robot purchasers. Initial feedback has been overwhelmingly positive, with particular strength in the education and senior care verticals. PCS-500 Elite continues to exceed expectations in healthcare applications following EU medical certification.

#### Industrial Automation Platform (IAP)

**Q1 2124 Revenue**: $3.7 billion (+19.4% YoY)

| Metric | Q1 2124 | Q1 2123 | Change |
|--------|---------|---------|--------|
| New Enterprise Customers | 98 | 82 | +19.5% |
| Total Enterprise Customers | 2,445 | 2,029 | +20.5% |
| Average Contract Value | $6.5M | $5.6M | +16.1% |
| Net Revenue Retention | 121% | 116% | +5 pts |
| Book-to-Bill Ratio | 1.18 | 1.12 | +5.4% |

**Key Contract Wins**:
| Customer | Industry | Value | Duration |
|----------|----------|-------|----------|
| Samsung Electronics | Manufacturing | $67M | 4 years |
| Maersk | Logistics | $43M | 3 years |
| Caterpillar | Heavy Equipment | $38M | 3 years |
| Home Depot | Retail | $29M | 5 years |

**Commentary**: IAP continues to benefit from accelerating automation investments across verticals. Manufacturing and logistics segments showed particular strength, while we are seeing emerging demand in agriculture and healthcare logistics. Project Atlas prototypes continue field testing with 3 additional pilot customers signed in Q1.

#### Neural Interface Modules (NIM)

**Q1 2124 Revenue**: $1.6 billion (+45.5% YoY)

| Metric | Q1 2124 | Q1 2123 | Change |
|--------|---------|---------|--------|
| Total Units Shipped | 156,000 | 112,000 | +39.3% |
| Healthcare Revenue | $1.1B | $0.7B | +57.1% |
| Research Revenue | $0.4B | $0.3B | +33.3% |
| Consumer Revenue | $0.1B | $0.1B | +0.0% |
| Operating Margin | 18.2% | 14.8% | +340 bps |

**Regulatory Progress**:
- Received regulatory approval in 4 additional Asian markets (South Korea, Taiwan, Thailand, Malaysia)
- FDA priority review granted for major depressive disorder indication
- Clinical trial enrollment progressing ahead of schedule for anxiety indication

**Commentary**: NIM delivered exceptional growth driven by healthcare adoption acceleration. The FDA priority review designation for depression treatment represents a significant milestone that could expand our addressable market by $4+ billion. We remain on track for NIM-6000 development completion in 2125.

#### Synthetic Consciousness Engine (SCE)

**Q1 2124 Revenue**: $0.8 billion (-11.1% YoY)

| Metric | Q1 2124 | Q1 2123 | Change |
|--------|---------|---------|--------|
| Enterprise Licenses | 768 | 802 | -4.2% |
| Developer Platform Users | 128,000 | 112,000 | +14.3% |
| OEM Partners | 49 | 44 | +11.4% |
| Renewal Rate | 98% | 96% | +2 pts |

**Commentary**: SCE revenue decline continues to reflect enterprise renewal timing. Underlying demand indicators remain strong with high renewal rates and growing developer platform usage. SCE 3.2 general availability in March brought enhanced multi-modal reasoning capabilities. SCE 4.0 development progressing well with private beta planned for Q4 2124.

### Balance Sheet Summary

| Metric | Mar 31, 2124 | Dec 31, 2123 | Change |
|--------|--------------|--------------|--------|
| Cash and equivalents | $4.8B | $4.2B | +14.3% |
| Short-term investments | $3.2B | $3.0B | +6.7% |
| Total debt | $4.3B | $4.5B | -4.4% |
| Net cash position | $3.7B | $2.7B | +37.0% |
| Stockholders' equity | $25.4B | $24.7B | +2.8% |

### Cash Flow Summary

| Metric | Q1 2124 | Q1 2123 |
|--------|---------|---------|
| Operating cash flow | $1.4B | $1.1B |
| Capital expenditures | ($0.5B) | ($0.4B) |
| Free cash flow | $0.9B | $0.7B |
| Share repurchases | ($0.3B) | ($0.2B) |
| Dividends paid | ($0.2B) | ($0.2B) |

### Q2 2124 Guidance

| Metric | Q2 2124 Guidance | Q2 2123 Actual | Implied Growth |
|--------|------------------|----------------|----------------|
| Revenue | $11.6B - $12.0B | $10.1B | +15-19% |
| Gross Margin | 51.0% - 52.0% | 50.5% | +50-150 bps |
| Operating Margin | 15.0% - 16.0% | 14.9% | +10-110 bps |
| Diluted EPS | $1.45 - $1.55 | $1.20 | +21-29% |

### FY 2124 Full Year Guidance (Reaffirmed)

| Metric | Guidance | Commentary |
|--------|----------|------------|
| Revenue | $46.5B - $47.5B | On track |
| Gross Margin | 51.0% - 52.0% | On track |
| Operating Margin | 15.0% - 16.0% | On track |
| Diluted EPS | $6.40 - $6.80 | On track |
| R&D Investment | ~$8.2B (17.5% of revenue) | On track |
| CapEx | $2.2B - $2.4B | On track |

---

# Q2 2124 Quarterly Report
## For the Quarter Ended June 30, 2124

### Executive Summary

Q2 2124 demonstrated continued strong execution across all segments. Revenue of $11.8 billion exceeded the high end of guidance, growing 16.8% year-over-year. The successful ramp of PCS-250, sustained IAP momentum, and accelerating NIM healthcare adoption drove outperformance. We are raising full-year guidance to reflect stronger-than-expected demand.

### Financial Highlights

| Metric | Q2 2124 | Q2 2123 | YoY Change |
|--------|---------|---------|------------|
| Revenue | $11.8B | $10.1B | +16.8% |
| Gross Profit | $6.1B | $5.1B | +19.6% |
| Gross Margin | 51.7% | 50.5% | +120 bps |
| Operating Income | $1.9B | $1.5B | +26.7% |
| Operating Margin | 16.1% | 14.9% | +120 bps |
| Net Income | $1.4B | $1.1B | +27.3% |
| Diluted EPS | $1.53 | $1.20 | +27.5% |
| Free Cash Flow | $1.2B | $0.9B | +33.3% |

### Non-GAAP Reconciliation

| Metric | Q2 2124 | Q2 2123 | Change |
|--------|---------|---------|--------|
| GAAP Net Income | $1.4B | $1.1B | +27.3% |
| Stock-based compensation | $0.23B | $0.20B | |
| Amortization of intangibles | $0.08B | $0.08B | |
| Restructuring charges | $0.01B | $0.02B | |
| Acquisition-related costs | $0.01B | $0.02B | |
| **Adjusted Net Income** | **$1.73B** | **$1.42B** | **+21.8%** |
| | | | |
| GAAP Diluted EPS | $1.53 | $1.20 | +27.5% |
| Non-GAAP adjustments | $0.14 | $0.14 | |
| **Adjusted Diluted EPS** | **$1.67** | **$1.34** | **+24.6%** |

### Revenue by Segment

| Segment | Q2 2124 | Q2 2123 | YoY Change | % of Total |
|---------|---------|---------|------------|------------|
| PCS | $4.8B | $4.2B | +14.3% | 40.7% |
| IAP | $3.9B | $3.2B | +21.9% | 33.1% |
| NIM | $1.7B | $1.3B | +30.8% | 14.4% |
| SCE | $0.9B | $0.8B | +12.5% | 7.6% |
| Other | $0.5B | $0.6B | -16.7% | 4.2% |
| **Total** | **$11.8B** | **$10.1B** | **+16.8%** | **100%** |

### Revenue by Geography

| Region | Q2 2124 | Q2 2123 | YoY Change | % of Total |
|--------|---------|---------|------------|------------|
| North America | $6.1B | $5.4B | +13.0% | 51.7% |
| Europe | $1.9B | $1.6B | +18.8% | 16.1% |
| Asia-Pacific | $3.0B | $2.4B | +25.0% | 25.4% |
| Rest of World | $0.8B | $0.7B | +14.3% | 6.8% |
| **Total** | **$11.8B** | **$10.1B** | **+16.8%** | **100%** |

### Segment Performance Details

#### Positronic Companion Series (PCS)

**Q2 2124 Revenue**: $4.8 billion (+14.3% YoY)

| Metric | Q2 2124 | Q2 2123 | Change |
|--------|---------|---------|--------|
| Units Shipped | 187,200 | 165,000 | +13.5% |
| Average Selling Price | $22,436 | $22,424 | +0.1% |
| Service Revenue | $1.2B | $1.1B | +9.1% |
| Operating Margin | 18.4% | 17.2% | +120 bps |

**Unit Breakdown**:
| Model | Q2 2124 | Q2 2123 | Change |
|-------|---------|---------|--------|
| PCS-400 | 148,000 | 152,000 | -2.6% |
| PCS-500 | 14,200 | 13,000 | +9.2% |
| PCS-250 | 25,000 | N/A | New |

**Commentary**: PCS-250 delivered a strong first full quarter with 25,000 units shipped, driving overall segment unit growth despite expected PCS-400 cannibalization. The product mix shift toward entry-level temporarily compressed blended ASP, but total revenue grew strongly. PCS v4 development remains on track for Q2 2125 launch.

#### Industrial Automation Platform (IAP)

**Q2 2124 Revenue**: $3.9 billion (+21.9% YoY)

| Metric | Q2 2124 | Q2 2123 | Change |
|--------|---------|---------|--------|
| New Enterprise Customers | 112 | 89 | +25.8% |
| Total Enterprise Customers | 2,557 | 2,118 | +20.7% |
| Average Contract Value | $6.8M | $5.8M | +17.2% |
| Net Revenue Retention | 124% | 118% | +6 pts |
| Backlog | $2.4B | $1.8B | +33.3% |

**Project Atlas Update**:
- 8 prototype units deployed across 6 pilot customers
- Rio Tinto pilot generating production data
- BHP Billiton expanded pilot scope
- 3 new pilot agreements signed totaling $78M

**Commentary**: IAP maintained exceptional momentum with book-to-bill of 1.24 and record backlog. Manufacturing and logistics verticals continue to lead, with mining emerging as a high-growth opportunity. Project Atlas pilots are generating valuable operational data and customer testimonials that will support commercial launch in H2 2124.

#### Neural Interface Modules (NIM)

**Q2 2124 Revenue**: $1.7 billion (+30.8% YoY)

| Metric | Q2 2124 | Q2 2123 | Change |
|--------|---------|---------|--------|
| Total Units Shipped | 167,600 | 126,600 | +32.4% |
| Healthcare Revenue | $1.2B | $0.9B | +33.3% |
| Research Revenue | $0.4B | $0.3B | +33.3% |
| Consumer Revenue | $0.1B | $0.1B | +0.0% |
| Operating Margin | 19.6% | 15.8% | +380 bps |

**Clinical and Regulatory Milestones**:
- FDA accepted NDA for major depressive disorder; PDUFA date set for February 2125
- Received regulatory approval in Indonesia and Vietnam
- Phase 3 clinical trial for generalized anxiety disorder completed enrollment
- NIM-6000 design phase completed; moving to prototype

**Commentary**: NIM continues to exceed expectations with healthcare adoption accelerating globally. The FDA acceptance of our depression NDA is a significant milestone that positions us for potential approval in H1 2125. Operating margin expansion reflects scale efficiencies and favorable product mix toward higher-margin medical-grade devices.

#### Synthetic Consciousness Engine (SCE)

**Q2 2124 Revenue**: $0.9 billion (+12.5% YoY)

| Metric | Q2 2124 | Q2 2123 | Change |
|--------|---------|---------|--------|
| Enterprise Licenses | 812 | 756 | +7.4% |
| Developer Platform Users | 134,000 | 116,000 | +15.5% |
| OEM Partners | 51 | 46 | +10.9% |
| Annual Contract Value | $4.4B | $3.9B | +12.8% |

**Commentary**: SCE returned to growth as expected with renewal timing normalization. Enterprise license count increased sequentially for the first time in three quarters. SCE 4.0 development is progressing well, with internal alpha testing underway and private beta planned for Q4 2124.

### Balance Sheet Summary

| Metric | Jun 30, 2124 | Mar 31, 2124 | Change |
|--------|--------------|--------------|--------|
| Cash and equivalents | $5.2B | $4.8B | +8.3% |
| Short-term investments | $3.4B | $3.2B | +6.3% |
| Total debt | $4.1B | $4.3B | -4.7% |
| Net cash position | $4.5B | $3.7B | +21.6% |
| Stockholders' equity | $26.8B | $25.4B | +5.5% |

### Cash Flow Summary

| Metric | Q2 2124 | Q2 2123 |
|--------|---------|---------|
| Operating cash flow | $1.8B | $1.4B |
| Capital expenditures | ($0.6B) | ($0.5B) |
| Free cash flow | $1.2B | $0.9B |
| Share repurchases | ($0.4B) | ($0.3B) |
| Dividends paid | ($0.2B) | ($0.2B) |

### Updated Full Year 2124 Guidance

| Metric | Previous | Updated | Change |
|--------|----------|---------|--------|
| Revenue | $46.5B - $47.5B | $47.8B - $48.2B | +$1.0B |
| Gross Margin | 51.0% - 52.0% | 51.0% - 52.0% | No change |
| Operating Margin | 15.0% - 16.0% | 15.5% - 16.5% | +50 bps |
| Diluted EPS | $6.40 - $6.80 | $6.80 - $7.20 | +$0.40 |
| R&D Investment | $8.2B | $8.5B | +$0.3B |
| CapEx | $2.2B - $2.4B | $2.4B | Narrowed |

### Q3 2124 Guidance

| Metric | Q3 2124 Guidance | Q3 2123 Actual | Implied Growth |
|--------|------------------|----------------|----------------|
| Revenue | $12.2B - $12.6B | $10.8B | +13-17% |
| Gross Margin | 51.0% - 52.0% | 50.2% | +80-180 bps |
| Operating Margin | 15.5% - 16.5% | 14.5% | +100-200 bps |
| Diluted EPS | $1.80 - $1.95 | $1.42 | +27-37% |

---

# Q3 2124 Quarterly Report
## For the Quarter Ended September 30, 2124

### Executive Summary

Q3 2124 marked another quarter of strong execution with revenue of $12.4 billion, exceeding the high end of our guidance range. Growth of 15.2% year-over-year was driven by continued NIM healthcare momentum, robust IAP enterprise demand, and seasonal strength in PCS. We are again raising our full-year outlook and entering Q4 with strong momentum.

### Financial Highlights

| Metric | Q3 2124 | Q3 2123 | YoY Change |
|--------|---------|---------|------------|
| Revenue | $12.4B | $10.8B | +15.2% |
| Gross Profit | $6.6B | $5.6B | +17.9% |
| Gross Margin | 53.2% | 51.9% | +130 bps |
| Operating Income | $2.1B | $1.77B | +18.4% |
| Operating Margin | 16.9% | 16.4% | +50 bps |
| Net Income | $1.71B | $1.42B | +20.4% |
| Diluted EPS | $1.87 | $1.54 | +21.4% |
| Free Cash Flow | $1.9B | $1.6B | +18.8% |

### Non-GAAP Reconciliation

| Metric | Q3 2124 | Q3 2123 | Change |
|--------|---------|---------|--------|
| GAAP Net Income | $1.71B | $1.42B | +20.4% |
| Stock-based compensation | $0.24B | $0.21B | |
| Amortization of intangibles | $0.07B | $0.08B | |
| Restructuring charges | $0.01B | $0.01B | |
| **Adjusted Net Income** | **$2.03B** | **$1.72B** | **+18.0%** |
| | | | |
| GAAP Diluted EPS | $1.87 | $1.54 | +21.4% |
| Non-GAAP adjustments | $0.17 | $0.16 | |
| **Adjusted Diluted EPS** | **$2.04** | **$1.70** | **+20.0%** |

### Revenue by Segment

| Segment | Q3 2124 | Q3 2123 | YoY Change | % of Total |
|---------|---------|---------|------------|------------|
| PCS | $5.2B | $4.7B | +10.6% | 41.9% |
| IAP | $4.3B | $3.6B | +19.4% | 34.7% |
| NIM | $2.0B | $1.5B | +33.3% | 16.1% |
| SCE | $0.9B | $1.0B | -10.0% | 7.3% |
| **Total** | **$12.4B** | **$10.8B** | **+15.2%** | **100%** |

### Revenue by Geography

| Region | Q3 2124 | Q3 2123 | YoY Change | % of Total |
|--------|---------|---------|------------|------------|
| North America | $6.4B | $5.6B | +14.3% | 51.6% |
| Europe | $2.1B | $1.8B | +16.7% | 16.9% |
| Asia-Pacific | $3.2B | $2.8B | +14.3% | 25.8% |
| Rest of World | $0.7B | $0.6B | +16.7% | 5.7% |
| **Total** | **$12.4B** | **$10.8B** | **+15.2%** | **100%** |

### Segment Performance Details

#### Positronic Companion Series (PCS)

**Q3 2124 Revenue**: $5.2 billion (+10.6% YoY)

| Metric | Q3 2124 | Q3 2123 | Change |
|--------|---------|---------|--------|
| Units Shipped | 198,000 | 178,000 | +11.2% |
| Average Selling Price | $22,727 | $22,472 | +1.1% |
| Service Revenue | $1.3B | $1.2B | +8.3% |
| Operating Margin | 18.6% | 17.8% | +80 bps |

**Seasonal Dynamics**: Q3 benefited from back-to-school demand for education applications and early holiday inventory builds by retailers. PCS-250 continued strong adoption with 28,000 units shipped.

**PCS v4 (Aurora) Development Update**:
- Feature freeze achieved in August 2124
- Beta testing initiated with 47 select customers
- Natural language interaction capabilities demonstrating 34% improvement in user satisfaction
- On track for Q2 2125 launch

**Commentary**: The PCS segment delivered solid growth driven by seasonal strength and continued PCS-250 success. We are particularly encouraged by the early feedback on PCS v4 beta testing, which suggests significant improvement in natural human-robot interaction.

#### Industrial Automation Platform (IAP)

**Q3 2124 Revenue**: $4.3 billion (+19.4% YoY)

| Metric | Q3 2124 | Q3 2123 | Change |
|--------|---------|---------|--------|
| New Enterprise Customers | 127 | 89 | +42.7% |
| Total Enterprise Customers | 2,684 | 2,207 | +21.6% |
| Average Contract Value | $7.1M | $6.0M | +18.3% |
| Net Revenue Retention | 124% | 119% | +5 pts |
| Backlog | $2.8B | $2.1B | +33.3% |

**Project Atlas Commercial Launch**:
- Full commercial launch announced September 15, 2124
- Initial orders of $147M received in first two weeks
- Rio Tinto contracted for 24 additional units ($89M)
- BHP, Vale, and Anglo American in active negotiations

**Commentary**: IAP achieved record new customer additions and expanded backlog to $2.8B. The successful commercial launch of Project Atlas opens a significant new market opportunity in heavy industrial automation. Early customer reception has exceeded expectations, with mining companies in particular showing strong demand.

#### Neural Interface Modules (NIM)

**Q3 2124 Revenue**: $2.0 billion (+33.3% YoY)

| Metric | Q3 2124 | Q3 2123 | Change |
|--------|---------|---------|--------|
| Total Units Shipped | 189,000 | 142,000 | +33.1% |
| Healthcare Revenue | $1.4B | $1.0B | +40.0% |
| Research Revenue | $0.5B | $0.4B | +25.0% |
| Consumer Revenue | $0.1B | $0.1B | +0.0% |
| Operating Margin | 21.2% | 17.4% | +380 bps |

**Regulatory and Clinical Progress**:
- Phase 3 anxiety trial primary endpoint met; NDA submission planned Q4 2124
- Regulatory approval received in Brazil and Mexico
- 12 new healthcare system partnerships signed
- NIM-6000 prototype completed; entering validation testing

**Commentary**: NIM continued exceptional growth with healthcare adoption accelerating across all regions. The positive Phase 3 anxiety results position us for NDA submission in Q4 and potential approval in H2 2125. We now have 847 healthcare system partnerships globally, up from 634 a year ago.

#### Synthetic Consciousness Engine (SCE)

**Q3 2124 Revenue**: $0.9 billion (-10.0% YoY)

| Metric | Q3 2124 | Q3 2123 | Change |
|--------|---------|---------|--------|
| Enterprise Licenses | 847 | 812 | +4.3% |
| Developer Platform Users | 142,000 | 122,000 | +16.4% |
| OEM Partners | 53 | 48 | +10.4% |
| Annual Contract Value | $4.5B | $4.1B | +9.8% |

**SCE 4.0 Development**:
- Private beta launched with 24 enterprise customers
- Incorporating Project Prometheus self-referential reasoning
- Performance benchmarks showing 2.4x improvement in complex reasoning tasks
- General availability planned for Q2 2125

**Commentary**: SCE revenue reflects continued renewal timing dynamics, though underlying metrics show healthy demand. The SCE 4.0 private beta is generating strong interest, with enterprise customers particularly excited about enhanced reasoning capabilities.

### Balance Sheet Summary

| Metric | Sep 30, 2124 | Jun 30, 2124 | Change |
|--------|--------------|--------------|--------|
| Cash and equivalents | $5.8B | $5.2B | +11.5% |
| Short-term investments | $3.6B | $3.4B | +5.9% |
| Total debt | $3.9B | $4.1B | -4.9% |
| Net cash position | $5.5B | $4.5B | +22.2% |
| Stockholders' equity | $28.4B | $26.8B | +6.0% |

### Cash Flow Summary

| Metric | Q3 2124 | Q3 2123 |
|--------|---------|---------|
| Operating cash flow | $2.4B | $2.0B |
| Capital expenditures | ($0.5B) | ($0.4B) |
| Free cash flow | $1.9B | $1.6B |
| Share repurchases | ($0.3B) | ($0.2B) |
| Dividends paid | ($0.2B) | ($0.2B) |

### Updated Full Year 2124 Guidance

| Metric | Previous | Updated | Change |
|--------|----------|---------|--------|
| Revenue | $47.8B - $48.2B | $48.0B - $48.5B | +$0.15B midpoint |
| Gross Margin | 51.0% - 52.0% | 52.0% - 53.0% | +100 bps |
| Operating Margin | 15.5% - 16.5% | 16.5% - 17.5% | +100 bps |
| Diluted EPS | $6.80 - $7.20 | $7.45 - $7.60 | +$0.53 midpoint |
| Free Cash Flow | $5.4B - $5.8B | $5.8B - $6.2B | +$0.4B |

### Q4 2124 Guidance

| Metric | Q4 2124 Guidance | Q4 2123 Actual | Implied Growth |
|--------|------------------|----------------|----------------|
| Revenue | $13.2B - $13.5B | $11.2B | +18-20% |
| Gross Margin | 52.5% - 53.5% | 52.8% | Flat to +70 bps |
| Operating Margin | 17.0% - 18.0% | 14.8% | +220-320 bps |
| Diluted EPS | $2.05 - $2.20 | $1.62 | +27-36% |

### Strategic Updates

**Project Prometheus**: Phase 3 integration progressing on schedule; consciousness indicator score improved to 0.72 from 0.68 in Q2.

**Quantum Dynamics Acquisition**: Regulatory review ongoing; expected close Q1 2125 pending approvals.

**Singapore R&D Campus**: Expansion groundbreaking completed; additional 250,000 sq ft of lab space expected operational H2 2125.

**AI Ethics**: Published annual AI Safety Report; established new External AI Ethics Advisory Board with 7 academic members.

---

## Conference Call Schedule

| Quarter | Date | Time | Dial-in | Webcast |
|---------|------|------|---------|---------|
| Q1 2124 | May 7, 2124 | 2:00 PM PT | 1-800-555-CALL | investors.soong-daystrom.com |
| Q2 2124 | August 5, 2124 | 2:00 PM PT | 1-800-555-CALL | investors.soong-daystrom.com |
| Q3 2124 | October 24, 2124 | 2:00 PM PT | 1-800-555-CALL | investors.soong-daystrom.com |
| Q4 2124 | February 6, 2125 | 2:00 PM PT | 1-800-555-CALL | investors.soong-daystrom.com |

---

## Investor Relations Contacts

**Michael Torres**
Vice President, Investor Relations
investor.relations@soong-daystrom.com
+1 (415) 555-7890

**Jennifer Kim**
Director, Investor Relations
jennifer.kim@soong-daystrom.com
+1 (415) 555-7891

---

*This report contains forward-looking statements. Actual results may differ materially from those projected. See our SEC filings for risk factors and additional disclosures.*

**Soong-Daystrom Industries, Inc.**
One Soong Plaza
San Francisco, CA 94105
www.soong-daystrom.com
